This proposal is the second revision of our competing renewal of our previous R01 studying dopamine pathology in schizophrenia. Based on the results of those studies we have turned our interest to the anatomical and neurochemical basis of treatment response or resistance. The typical symptoms of schizophrenia are psychosis, cognitive impairments and negative symptoms, and the treatment available is based in the use of antipsychotic medications, which primarily act blocking dopamine receptors in some degree. Unfortunately, not all patients respond to treatment, and in those who do, only psychotic symptoms are usually improved. In fact, approximately 30% of patients do not respond to these treatments at all, and are considered treatment-non-responders or treatment resistant. This clearly points out the need of finding the basis of these differences in treatment response in order to develop new therapies. The basis of these differences are currently unknown but some lines of evidence (including work performed by our group), point towards different dopamine anomalies ('dopamine phenotypes"""""""") in treatment-responders vs treatment-non- responders (Abi-Dargham et al, 2000;Roberts et al, 2009). The overall goal of this proposal is to identify components of the dopaminergic transmission that may underlie the existence of different """"""""dopamine phenotypes"""""""" in treatment-responders vs treatment-non- responders. We propose a multitier approach to analyze dopamine pathologies in postmortem substantia nigra-ventral tegmental area (SN/VTA), [the area of the brain that houses the majority of the dopaminergic cells], in schizophrenia treatment-responders vs treatment-non-responders, comparing also with healthy controls. We will test the capability of these dopamine neurons to produce dopamine, the health of the dopamine cell populations, and the modulation of these cells by the glutamatergic system, all with the common goal of identifying specific anomalies that can be linked to success/failure in treatment response. Even when dopamine has a central role in schizophrenia pathology, there are very scarce studies on anomalies of the SN/VTA in schizophrenia, and even rarer is the study of treatment response in postmortem human brain, both facts making our project unique. More importantly, finding neuroanatomical and neurochemical biomarkers of treatment response should allow the identification of potential targets for the development of new and more specific therapies, as well as provide a framework for the development of neuroimaging tools aimed to the prediction of treatment response outcomes.
Identifying the neuroanatomical and neurochemical substrates underlying treatment response/resistance to the currently available antipsychotic medications in schizophrenia should provide new potential targets for treatment intervention, as well as a framework to develop tools for the prediction of treatment outcomes.
|Walker, Courtney K; Roche, Joy K; Sinha, Vidushi et al. (2017) Substantia nigra ultrastructural pathology in schizophrenia. Schizophr Res :|
|Roberts, Rosalinda C (2017) Postmortem studies on mitochondria in schizophrenia. Schizophr Res 187:17-25|
|Schoonover, Kirsten E; McCollum, Lesley A; Roberts, Rosalinda C (2017) Protein Markers of Neurotransmitter Synthesis and Release in Postmortem Schizophrenia Substantia Nigra. Neuropsychopharmacology 42:540-550|
|McCollum, Lesley A; McCullumsmith, Robert E; Roberts, Rosalinda C (2016) Tyrosine hydroxylase localization in the nucleus accumbens in schizophrenia. Brain Struct Funct 221:4451-4458|
|Rice, Matthew W; Roberts, Rosalinda C; Melendez-Ferro, Miguel et al. (2016) Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia. Brain Struct Funct 221:185-201|
|McCollum, Lesley A; Roberts, Rosalinda C (2015) Uncovering the role of the nucleus accumbens in schizophrenia: A postmortem analysis of tyrosine hydroxylase and vesicular glutamate transporters. Schizophr Res 169:369-373|
|McCollum, Lesley A; Walker, Courtney K; Roche, Joy K et al. (2015) Elevated Excitatory Input to the Nucleus Accumbens in Schizophrenia: A Postmortem Ultrastructural Study. Schizophr Bull 41:1123-32|
|McCollum, L A; Roberts, R C (2014) Ultrastructural localization of tyrosine hydroxylase in tree shrew nucleus accumbens core and shell. Neuroscience 271:23-34|
|Rice, Matthew W; Smith, Kristen L; Roberts, Rosalinda C et al. (2014) Assessment of cytochrome C oxidase dysfunction in the substantia nigra/ventral tegmental area in schizophrenia. PLoS One 9:e100054|
|Bolding, Mark S; Reid, Meredith A; Avsar, Kathy B et al. (2013) Magnetic transfer contrast accurately localizes substantia nigra confirmed by histology. Biol Psychiatry 73:289-94|
Showing the most recent 10 out of 27 publications